Abstract
IntroductionTo estimating the seroprevalence of HIV, hepatitis B, hepatitis C and syphilis among blood donors in the Aïoun hospital.MethodsThis is a retrospective study from 1 January 2010 to 31 December 2015.ResultsOn the five-year study period, 1,123 donors were collected. Of these, 182 were HIV-positive, an overall prevalence of 16.2% with predominance in male with a sex ratio Man/Woman of 5.2. The average age of donors was 32.7 ± 10 years (range 17-73 years). The most represented that age group 21-30 years (40.5%). The seroprevalence found were 1.2% for HIV, 11.8% for HBV, HCV 0.2% and 3% for syphilis. Co-infection was found in 0.7% of which 0.5% of dual HIV HBV/Syphilis and 0.2% in HBV/HIV.ConclusionThe transmission of infectious agents related to transfusion represents the greatest threat to transfusion safety of the recipient. Therefore, a rigorous selection and screening of blood donors are highly recommended to ensure blood safety for the recipient.
Highlights
Blood transfusion is a medical therapeutic act [1,2,3]
Despite the benefits, each patient is transfused at risk for transfusion-transmissible infections, mainly HIV, hepatitis B (HBV), hepatitis C (HCV) and Trepanoma pallidum (T. pallidum) [2, 3]
Seropositivity for syphilis in turn uses a completely screening by a Rapid-Plasma-Réagin test the positive samples were passed to the TPHA (Treponema Pallidum Hemagglutination Assay) and the Venereal Disease Research Laboratory (VDRL), for confirmation
Summary
Blood transfusion is a medical therapeutic act [1,2,3]. Despite the benefits, each patient is transfused at risk for transfusion-transmissible infections, mainly HIV, hepatitis B (HBV), hepatitis C (HCV) and Trepanoma pallidum (T. pallidum) [2, 3]. The morbidity and mortality resulting from transfusion have serious consequences, for the beneficiaries themselves and for their families, their communities and society in general [3, 4]. This study has aimed to update the seroprevalence data of 4 serological markers (HIV, HBV, HCV, anti-Ag-Trepanoma pallidum) tested in blood donors from the hospital Aïoun, in accordance with national strategy for patient safety
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
